Novartis' proactive CHMP stance is supported by the results of key REPLENISH III phase trials
2026-09-18 23:03:02
According to CoinMeta, as reported by Reuters, Novartis' ( Novartis Ag ) positive feedback from the European Medicines Agency ( CHMP ) has been supported by the results of a key REPLENISH III phase of trials.
Bullish 0
Bearish 0
Source:Internet
This content is for market information only and does not constitute investment advice.